QUOTED. Michael Mussallem.
Executive Summary
During the annual J.P. Morgan Healthcare Conferences on 10 January, Edwards Lifesciences CEO Michael Mussallem affirmed previous revenue guidance and discussed plans for 2022.
“We expect [2022] to be a year of significant milestone achievements and a lot of investments in our future." – Michael Mussallem, CEO, Edwards Lifesciences
- Find out more: JPM 2022: Dexcom, Edwards, J&J, Medtronic, ResMed
Click here for a free trial of Medtech Insight